A--The United States Army Medical Research Acquisitions Activity on behalf of the U.S. Army Medical Material Development Activity, is issuing a Notice of Intent to Award a Sole Source contract.

The contract involves a sole source award to support a Phase 2/3 randomized, double-blind, controlled clinical trial of riluzole as a neuroprotective treatment for acute spinal cord injury (SCI). This initiative is led by Methodist Hospital in collaboration with the Christopher and Dana Reeve Foundation and is coordinated through the United States Army Medical Research Acquisitions Activity on behalf of the U.S. Army Medical Material Development Activity. The trial aims to assess the efficacy and safety of riluzole in improving outcomes for patients with acute SCI. This notice, issued on March 23, 2015, indicates that the contract will be awarded without further competition, emphasizing that it is not a request for proposals and does not commit the government to any costs associated with the preparation or submission of data. The contract relates to professional, scientific, and technical services under the NAICS code 541711. Overall, the action underscores the intent to move forward swiftly with this important clinical research effort to explore potential treatments for SCI.